• Wave Life Sciences launched a Phase 2a trial testing WVE-007 with weekly tirzepatide in adults with obesity and type 2 diabetes.
• Earlier preclinical results were presented at ObesityWeek 2025, supporting greater weight loss in combination than with GLP-1 therapy alone.
• Clinical data to date suggest fat loss without muscle loss, supporting an infrequent dosing approach for WVE-007.
• The study expands WVE-007 into combination use, a key step toward broader positioning across obesity and related cardiometabolic indications.
• A separate maintenance study to limit weight regain after stopping incretin therapy is slated to start in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230730PRIMZONEFULLFEED9832139) on September 23, 2026, and is solely responsible for the information contained therein.